Oncoshot

Astrazeneca

www.astrazeneca.com

About

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - oncology, cardiovascular, renal and metabolism, as well as respiratory and immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the company on Twitter @AstraZeneca.

See the video about us on Facebook

Branches

AstraZeneca Global Commercial | Singapore Marketing Company

10 Kallang Avenue #12-10, Aperia Tower 2, Singapore 339510

+65 6812 4700

Mon—Fri: 9:00 AM—5:30 PM

Key Trials

2 trials shown

Astrazeneca

Key trial

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

24 July 2020

This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.

Trial number:: NCT04494425

Study type:: Targeted therapy

Trial phase:: 3

Overall status:: Recruiting

Astrazeneca

Key trial

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

25 June 2019

Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)

Trial number:: NCT03997123

Study type:: Targeted therapy, Chemotherapy

Trial phase:: 3

Overall status:: Recruiting